Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response
We assessed the avidity maturation process elicited by human immunization with alum-adsorbed HBsAg alone or with a novel adjuvant containing CpG motifs (CpG 7909). Mean avidity indexes and distribution of low- and high-avidity anti-HBs indicated that avidity maturation essentially takes place late a...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2004-12, Vol.23 (5), p.615-622 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 622 |
|---|---|
| container_issue | 5 |
| container_start_page | 615 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Siegrist, Claire-Anne Pihlgren, Maria Tougne, Chantal Efler, Sue M. Morris, Mary Lou AlAdhami, Mohammed J. Cameron, D. William Cooper, Curtis L. Heathcote, Jenny Davis, Heather L. Lambert, Paul-Henri |
| description | We assessed the avidity maturation process elicited by human immunization with alum-adsorbed HBsAg alone or with a novel adjuvant containing CpG motifs (CpG 7909). Mean avidity indexes and distribution of low- and high-avidity anti-HBs indicated that avidity maturation essentially takes place late after priming. CpG 7909 markedly enhanced this affinity maturation process, increasing the pool of high-avidity antibodies. The influence of CpG 7909 was antigen-specific, isotype-specific and distinct from the influence on anti-HBs production, as avidity did not correlate with anti-HBs IgG titers. This is the first demonstration that a novel human adjuvant may induce antibodies with higher antigen-binding affinity. |
| doi_str_mv | 10.1016/j.vaccine.2004.07.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67078129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X04005298</els_id><sourcerecordid>67078129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-3182ac52fe4c31da36517cb63152d91ec0ca0e8d83099af4c1da815d81074e1b3</originalsourceid><addsrcrecordid>eNqFkU-L1TAUxYMozpvRj6AExNm15iZN_6xkfOgoDLhRcBfy0ltfHm1Sk3Rgtn5yU15hwM2sciG_czn3HELeACuBQf3hVN5rY6zDkjNWlawpGVTPyA7aRhRcQvuc7Bivq6IC9uuCXMZ4YoxJAd1LcgFSVhxa2JG_e1_ofrLOxhR0st5RP9D9fEv9aH97t5gRfbI9RoruqJ3JQzoiHXVCqochC9MDnXRaNvUcfGbiuuW4TNpR7ZItjjjn72Qj_UQ33zRgnL2L-Iq8GPQY8fX2XpGfXz7_2H8t7r7fftvf3BUmX5MKAS3XRvIBKyOg16KW0JhDLUDyvgM0zGiGbd8K1nV6qExmWpB9C6ypEA7iilyf92aLfxaMSU02GhxH7dAvUdUNa1rg3ZMgNJx3vFvBd_-BJ78El49QOeGO1dniSskzZYKPMeCg5mAnHR4UMLV2qU5qy0StXSrWqNxl1r3dti-HCftH1VZeBt5vgI5Gj0PI9dj4yNUiZyTrzH08c5jTvbcYVDQWc5W9DWiS6r19wso_q3_A4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559066519</pqid></control><display><type>article</type><title>Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Siegrist, Claire-Anne ; Pihlgren, Maria ; Tougne, Chantal ; Efler, Sue M. ; Morris, Mary Lou ; AlAdhami, Mohammed J. ; Cameron, D. William ; Cooper, Curtis L. ; Heathcote, Jenny ; Davis, Heather L. ; Lambert, Paul-Henri</creator><creatorcontrib>Siegrist, Claire-Anne ; Pihlgren, Maria ; Tougne, Chantal ; Efler, Sue M. ; Morris, Mary Lou ; AlAdhami, Mohammed J. ; Cameron, D. William ; Cooper, Curtis L. ; Heathcote, Jenny ; Davis, Heather L. ; Lambert, Paul-Henri</creatorcontrib><description>We assessed the avidity maturation process elicited by human immunization with alum-adsorbed HBsAg alone or with a novel adjuvant containing CpG motifs (CpG 7909). Mean avidity indexes and distribution of low- and high-avidity anti-HBs indicated that avidity maturation essentially takes place late after priming. CpG 7909 markedly enhanced this affinity maturation process, increasing the pool of high-avidity antibodies. The influence of CpG 7909 was antigen-specific, isotype-specific and distinct from the influence on anti-HBs production, as avidity did not correlate with anti-HBs IgG titers. This is the first demonstration that a novel human adjuvant may induce antibodies with higher antigen-binding affinity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2004.07.014</identifier><identifier>PMID: 15542181</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Adolescent ; Adult ; Antibodies ; Antibody Affinity ; Antibody Specificity - immunology ; Antigens ; Applied microbiology ; B lymphocytes ; Biological and medical sciences ; Female ; Fundamental and applied biological sciences. Psychology ; Hepatitis B Antibodies - immunology ; Hepatitis B Surface Antigens - immunology ; Hepatitis B Vaccines - administration & dosage ; Hepatitis B Vaccines - immunology ; Hepatitis B virus ; Human ; Human viral diseases ; Humans ; Immune system ; Immunization ; Immunoglobulin G - blood ; Immunoglobulin G - immunology ; Infectious diseases ; Influence ; Male ; Medical sciences ; Microbiology ; Oligodeoxyribonucleotides - administration & dosage ; Tetanus ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Viral diseases ; Viral hepatitis</subject><ispartof>Vaccine, 2004-12, Vol.23 (5), p.615-622</ispartof><rights>2004 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Elsevier Limited Dec 16, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-3182ac52fe4c31da36517cb63152d91ec0ca0e8d83099af4c1da815d81074e1b3</citedby><cites>FETCH-LOGICAL-c518t-3182ac52fe4c31da36517cb63152d91ec0ca0e8d83099af4c1da815d81074e1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X04005298$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16336556$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15542181$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Siegrist, Claire-Anne</creatorcontrib><creatorcontrib>Pihlgren, Maria</creatorcontrib><creatorcontrib>Tougne, Chantal</creatorcontrib><creatorcontrib>Efler, Sue M.</creatorcontrib><creatorcontrib>Morris, Mary Lou</creatorcontrib><creatorcontrib>AlAdhami, Mohammed J.</creatorcontrib><creatorcontrib>Cameron, D. William</creatorcontrib><creatorcontrib>Cooper, Curtis L.</creatorcontrib><creatorcontrib>Heathcote, Jenny</creatorcontrib><creatorcontrib>Davis, Heather L.</creatorcontrib><creatorcontrib>Lambert, Paul-Henri</creatorcontrib><title>Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>We assessed the avidity maturation process elicited by human immunization with alum-adsorbed HBsAg alone or with a novel adjuvant containing CpG motifs (CpG 7909). Mean avidity indexes and distribution of low- and high-avidity anti-HBs indicated that avidity maturation essentially takes place late after priming. CpG 7909 markedly enhanced this affinity maturation process, increasing the pool of high-avidity antibodies. The influence of CpG 7909 was antigen-specific, isotype-specific and distinct from the influence on anti-HBs production, as avidity did not correlate with anti-HBs IgG titers. This is the first demonstration that a novel human adjuvant may induce antibodies with higher antigen-binding affinity.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies</subject><subject>Antibody Affinity</subject><subject>Antibody Specificity - immunology</subject><subject>Antigens</subject><subject>Applied microbiology</subject><subject>B lymphocytes</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hepatitis B Antibodies - immunology</subject><subject>Hepatitis B Surface Antigens - immunology</subject><subject>Hepatitis B Vaccines - administration & dosage</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>Hepatitis B virus</subject><subject>Human</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunization</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulin G - immunology</subject><subject>Infectious diseases</subject><subject>Influence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Oligodeoxyribonucleotides - administration & dosage</subject><subject>Tetanus</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU-L1TAUxYMozpvRj6AExNm15iZN_6xkfOgoDLhRcBfy0ltfHm1Sk3Rgtn5yU15hwM2sciG_czn3HELeACuBQf3hVN5rY6zDkjNWlawpGVTPyA7aRhRcQvuc7Bivq6IC9uuCXMZ4YoxJAd1LcgFSVhxa2JG_e1_ofrLOxhR0st5RP9D9fEv9aH97t5gRfbI9RoruqJ3JQzoiHXVCqochC9MDnXRaNvUcfGbiuuW4TNpR7ZItjjjn72Qj_UQ33zRgnL2L-Iq8GPQY8fX2XpGfXz7_2H8t7r7fftvf3BUmX5MKAS3XRvIBKyOg16KW0JhDLUDyvgM0zGiGbd8K1nV6qExmWpB9C6ypEA7iilyf92aLfxaMSU02GhxH7dAvUdUNa1rg3ZMgNJx3vFvBd_-BJ78El49QOeGO1dniSskzZYKPMeCg5mAnHR4UMLV2qU5qy0StXSrWqNxl1r3dti-HCftH1VZeBt5vgI5Gj0PI9dj4yNUiZyTrzH08c5jTvbcYVDQWc5W9DWiS6r19wso_q3_A4g</recordid><startdate>20041216</startdate><enddate>20041216</enddate><creator>Siegrist, Claire-Anne</creator><creator>Pihlgren, Maria</creator><creator>Tougne, Chantal</creator><creator>Efler, Sue M.</creator><creator>Morris, Mary Lou</creator><creator>AlAdhami, Mohammed J.</creator><creator>Cameron, D. William</creator><creator>Cooper, Curtis L.</creator><creator>Heathcote, Jenny</creator><creator>Davis, Heather L.</creator><creator>Lambert, Paul-Henri</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20041216</creationdate><title>Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response</title><author>Siegrist, Claire-Anne ; Pihlgren, Maria ; Tougne, Chantal ; Efler, Sue M. ; Morris, Mary Lou ; AlAdhami, Mohammed J. ; Cameron, D. William ; Cooper, Curtis L. ; Heathcote, Jenny ; Davis, Heather L. ; Lambert, Paul-Henri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-3182ac52fe4c31da36517cb63152d91ec0ca0e8d83099af4c1da815d81074e1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies</topic><topic>Antibody Affinity</topic><topic>Antibody Specificity - immunology</topic><topic>Antigens</topic><topic>Applied microbiology</topic><topic>B lymphocytes</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hepatitis B Antibodies - immunology</topic><topic>Hepatitis B Surface Antigens - immunology</topic><topic>Hepatitis B Vaccines - administration & dosage</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>Hepatitis B virus</topic><topic>Human</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunization</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulin G - immunology</topic><topic>Infectious diseases</topic><topic>Influence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Oligodeoxyribonucleotides - administration & dosage</topic><topic>Tetanus</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siegrist, Claire-Anne</creatorcontrib><creatorcontrib>Pihlgren, Maria</creatorcontrib><creatorcontrib>Tougne, Chantal</creatorcontrib><creatorcontrib>Efler, Sue M.</creatorcontrib><creatorcontrib>Morris, Mary Lou</creatorcontrib><creatorcontrib>AlAdhami, Mohammed J.</creatorcontrib><creatorcontrib>Cameron, D. William</creatorcontrib><creatorcontrib>Cooper, Curtis L.</creatorcontrib><creatorcontrib>Heathcote, Jenny</creatorcontrib><creatorcontrib>Davis, Heather L.</creatorcontrib><creatorcontrib>Lambert, Paul-Henri</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siegrist, Claire-Anne</au><au>Pihlgren, Maria</au><au>Tougne, Chantal</au><au>Efler, Sue M.</au><au>Morris, Mary Lou</au><au>AlAdhami, Mohammed J.</au><au>Cameron, D. William</au><au>Cooper, Curtis L.</au><au>Heathcote, Jenny</au><au>Davis, Heather L.</au><au>Lambert, Paul-Henri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-12-16</date><risdate>2004</risdate><volume>23</volume><issue>5</issue><spage>615</spage><epage>622</epage><pages>615-622</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>We assessed the avidity maturation process elicited by human immunization with alum-adsorbed HBsAg alone or with a novel adjuvant containing CpG motifs (CpG 7909). Mean avidity indexes and distribution of low- and high-avidity anti-HBs indicated that avidity maturation essentially takes place late after priming. CpG 7909 markedly enhanced this affinity maturation process, increasing the pool of high-avidity antibodies. The influence of CpG 7909 was antigen-specific, isotype-specific and distinct from the influence on anti-HBs production, as avidity did not correlate with anti-HBs IgG titers. This is the first demonstration that a novel human adjuvant may induce antibodies with higher antigen-binding affinity.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15542181</pmid><doi>10.1016/j.vaccine.2004.07.014</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-12, Vol.23 (5), p.615-622 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67078129 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvants, Immunologic - administration & dosage Adolescent Adult Antibodies Antibody Affinity Antibody Specificity - immunology Antigens Applied microbiology B lymphocytes Biological and medical sciences Female Fundamental and applied biological sciences. Psychology Hepatitis B Antibodies - immunology Hepatitis B Surface Antigens - immunology Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - immunology Hepatitis B virus Human Human viral diseases Humans Immune system Immunization Immunoglobulin G - blood Immunoglobulin G - immunology Infectious diseases Influence Male Medical sciences Microbiology Oligodeoxyribonucleotides - administration & dosage Tetanus Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral hepatitis |
| title | Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T12%3A27%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Co-administration%20of%20CpG%20oligonucleotides%20enhances%20the%20late%20affinity%20maturation%20process%20of%20human%20anti-hepatitis%20B%20vaccine%20response&rft.jtitle=Vaccine&rft.au=Siegrist,%20Claire-Anne&rft.date=2004-12-16&rft.volume=23&rft.issue=5&rft.spage=615&rft.epage=622&rft.pages=615-622&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2004.07.014&rft_dat=%3Cproquest_cross%3E67078129%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559066519&rft_id=info:pmid/15542181&rft_els_id=S0264410X04005298&rfr_iscdi=true |